Pharmaceutical Technology

JULY 7, 2022

But scientists have struggled to find effective treatments for many of these diseases since the dawn of modern medicine. Although a high number of cell and gene therapies are in early-stage development, a new wave of approvals could be on its way. Securing the supply chain. The industry is moving at an unprecedented speed.

Gene Therapy 245

Gene Therapy Gene Medicine Genetics 245

Pharmaceutical Technology

MAY 30, 2023

SK Bioscience has received marketing authorisation from the UK’s medicines and healthcare products regulatory agency (MHRA) for its Covid-19 vaccine, SKYCovion. SKYCovion, a protein-based vaccine created in collaboration with GSK’s pandemic adjuvant, is suitable for storage between 2° and 8° Celsius.

Vaccination 298

Vaccination Vaccine Protein Medicine 298

Pharmaceutical Technology

DECEMBER 16, 2022

Previously disrupted by the Covid-19 pandemic, this past year has seen a return of increased efforts and progress in the development of new treatments for tropical diseases. Both vaccines are based on recombinant proteins and attack the parasite during the sporozoite stage.

Development 264

Development Drugs Vaccine Vaccination 264

Pharmaceutical Technology

APRIL 13, 2023

Clinical-stage biopharmaceutical firm Alentis Therapeutics has raised $105m in a Series C financing round for advancing transformational medicines targeting the CLAUDIN-1 protein. The latest financing round comes after the company received $67m in Series B funding in June 2021.

Medicine 130

Medicine Development Antibody Engineer 130

Pharmaceutical Technology

AUGUST 5, 2022

The development of therapeutics for transmissible spongiform encephalopathies (TSEs) continues to be challenged by the complex nature of these diseases. As per the prevailing prion theory, a misfolded version of a normal cell-surface protein acts as the chief infectious agent.

Drugs 299

Drugs Protein Vaccination Vaccine 299

Pharmaceutical Technology

MAY 11, 2023

Bayer has entered a strategic collaboration agreement with biotechnology company Bicycle Therapeutics to discover, develop, manufacture and commercialise Bicycle’s radioconjugates for a number of oncology targets. Bicycle will receive an upfront payment of $45m and up to $1.7bn as potential development and commercially based milestone fees.

Development 162

Development Manufacturing Protein Clinical Development 162

Pharmaceutical Technology

JANUARY 3, 2023

Blacksmith Medicines has signed a definitive merger agreement with Forge Therapeutics to create a combined entity that will discover and develop medicines targeting a large class of proteins called metalloenzymes. The merged entity will focus on developing medicines with an initial focus on oncology and infection.

Medicine 130

Medicine DNA Genomics Genome 130

Camargo

NOVEMBER 29, 2021

The development of biological products (or biologics) represents a major advancement in modern medicine, enabling the treatment of patients with many illnesses where no other therapeutics were previously available. Recombinant therapeutic proteins. Fusion proteins. Gene and cellular therapies. Growth factors. Interferons.

Development 180

Development Protein Production Hormones 180

Pharmaceutical Technology

JULY 6, 2022

A protein-based vaccine, NVX-CoV2373 is made from the genetic sequence of the SARS-CoV-2 virus’ first strain. The latest development comes after the Committee for Medicinal Products for Human Use of the European Medicines Agency granted a positive recommendation in June this year.

Vaccination 264

Vaccination Vaccine Protein Clinical Trials 264

Pharmaceutical Technology

JULY 21, 2022

The company received fast-track designation from the US Food and Drug Administration (FDA) for the eltanexor development programme as a single agent to treat relapsed or refractory intermediate, high or very high-risk MDS patients. Eltanexor is a new oral selective inhibitor of nuclear export (SINE) compound.

Clinical Trials 264

Clinical Trials Clinical Trials Protein Production 264

Pharmaceutical Technology

APRIL 5, 2023

Absci has collaborated with bioinformatics firm M2GEN to expedite the development of new cancer medicines. Absci stated that this collaboration combines AI drug creation technology and oncology bioinformatics, thereby reducing the time and cost of cancer drug development.

Development 130

Development Bioinformatics Drugs Immune Response 130

Pharmaceutical Technology

NOVEMBER 11, 2022

The European Commission (EC) has granted approval for Sanofi and GSK ’s monovalent, recombinant-protein-based, adjuvanted Covid-19 vaccine, VidPrevtyn Beta, as a booster in adults aged 18 years and above. It is indicated as a booster in people of this age group who were earlier inoculated with a Covid-19 vaccine.

Vaccination 246

Vaccination Vaccine Immune Response Protein 246

XTalks

NOVEMBER 26, 2024

This progressive disease occurs when misfolded transthyretin (TTR) proteins form amyloid deposits in the heart, leading to cardiac dysfunction. A Marketing Authorization Application has been submitted to the European Medicines Agency (EMA), with a decision anticipated in 2025.

Genetic Disease 105

Genetic Disease Genetics Protein Clinical Development 105

Pharmaceutical Technology

MAY 26, 2023

HanAll Biopharma and Daewoong Pharmaceutical have entered into a co-development deal with NurrOn Pharmaceuticals to develop therapy for Parkinson’s disease (PD) and other neurodegenerative disorders. Nurr1 is a class of proteins important for the development and maintenance of dopamine in the brain.

Development 130

Development Clinical Trials Clinical Trials Protein 130

Pharmaceutical Technology

OCTOBER 18, 2022

Last week, Nature magazine published a paper detailing an in-situ study of Parkinson’s disease (PD), showing protein structural changes in cerebrospinal fluid (CSF) between healthy individuals and Parkinson’s patients. Technology such as RT QuIC has been developed to detect alpha synuclein within CSF. The search for PD biomarkers.

Protein 264

Protein Genetics Gene Clinical Research 264

Pharmaceutical Technology

SEPTEMBER 14, 2022

API peptides and proteins-based drugs have gained much attention in the past decade. Victoza, Copaxone, Lupron, Zoladex, Sandostatin, and Somatuline are some of the popularly marketed peptide API therapeutic drugs while more than 600 peptide-based pharmacological leads are being investigated worldwide, across various phases of development.

Protein 100

Protein Marketing Manufacturing Reagent 100

Pharmaceutical Technology

APRIL 27, 2023

Orbital will use the new funding to increase the application of RNA-based medicines for use in the fields of new vaccines, immunomodulation and protein replacement. The company is currently developing an RNA platform capable of combining well-known and upcoming RNA technologies and delivery systems.

RNA 130

RNA Medicine Gene Therapy Gene 130

Pharmaceutical Technology

JUNE 28, 2022

grant from the National Institutes of Health (NIH) unit National Institute of Allergy and Infectious Diseases (NIAID) for developing a Covid-19 oral antiviral drug. The Rensselaer team will partner with researchers from the Scripps Research Institute, Mount Sinai School of Medicine and the University of Bologna, Italy for this research.

Development 147

Development Bioinformatics Drugs Allergies 147

Pharmaceutical Technology

AUGUST 17, 2022

VLA15 is the only vaccine for Lyme disease in clinical development, according to GlobalData, the parent company of Pharmaceutical Technology. In the last 20 years, this is the biggest buzz in the vaccine market for Lyme disease,” said Yale School of Medicine associate professor Sukanya Narasimhan, PhD, about the Phase III VLA15 trial.

Vaccination 299

Vaccination Vaccine Bacteria Protein 299

Pharmaceutical Technology

APRIL 28, 2023

Generate Biomedicines has signed a co-development and commercialisation agreement with the University of Texas MD Anderson Cancer Center to expedite the development of new protein therapeutics for oncology using generative AI. TRACTION is a part of the therapeutics discovery division of MD Anderson.

Development 130

Development Clinical Trials Clinical Trials Protein 130

Pharmaceutical Technology

JUNE 29, 2022

The next wave of medicine is well on course to be cell and gene-based. In September 2021, GlobalData figures revealed there to be 1,320 industry-sponsored regenerative medicine and advanced therapy trials ongoing worldwide. Developing best-in-class speciality enzymes.

Drugs 295

Drugs Gene Therapy Production Manufacturing 295

XTalks

DECEMBER 12, 2023

Plasma medicine is a critical and specialized field within healthcare, centering on the use of human plasma for the development and administration of life-saving treatments. When people think about innovation drivers in global healthcare, they often think of “big pharma,” and not necessarily companies in the plasma medicines space.

Medicine 111

Medicine Recombinant Antibody Protein Antibody 111

Pharmaceutical Technology

OCTOBER 3, 2022

Indonesia has granted Emergency Use Authorization (EUA) for the patent-free Covid-19 vaccine, IndoVac, developed by the Texas Children’s Hospital Center for Vaccine Development (CVD) and Baylor College of Medicine, US. PT Bio Farma will manufacture 20 million doses of the vaccine this year.

Vaccination 130

Vaccination Vaccine Development Production 130

XTalks

MARCH 10, 2025

The FDA has approved Genentechs TNKase (tenecteplase) for the treatment of acute ischemic stroke in adults, marking a milestone as the first new stroke medicine approved in nearly three decades. TNKase works by initiating a biochemical reaction that breaks down fibrin, a protein that acts like the scaffolding holding blood clots together.

Medicine 59

Medicine Trials Pharmacy Clinical Trials 59

XTalks

DECEMBER 10, 2024

Rilzabrutinib works by targeting BTK, a protein involved in immune cell communication. By inhibiting this protein, the drug disrupts pathways that contribute to platelet destruction and insufficient production. percent platelet response in a study published in The New England Journal of Medicine.

Trials 104

Trials Protein Clinical Development Drugs 104

pharmaphorum

SEPTEMBER 14, 2020

Here he gives us a deeper look at how genomic medicine is evolving and the barriers that are preventing it from reaching its full potential. At that time, we thought this would be the holy grail for medicine. Now, however, the field is changing with respect to genomic medicine.

Genomics 119

Genomics Genome Medicine Gene 119

Pharmaceutical Technology

FEBRUARY 3, 2023

The failure of several late-stage trials highlights the challenging nature of HIV vaccine development. Since HIV integrates with the DNA, eliminating the virus from the body is very difficult, explains David Montefiori, PhD, director of the Laboratory for AIDS Vaccine Research and Development at Duke University in Durham, North Carolina.

Vaccination 293

Vaccination Vaccine Antibody Trials 293

Pharma Mirror

APRIL 21, 2024

With the rapid development of biotechnology and molecular medicine, the introduction of mRNA as a vaccine or therapeutic agent enables the production of almost any desired functional protein/peptide within the human body.

In-Vitro 130

In-Vitro Drugs Genetic Disease RNA 130

Pharmaceutical Technology

MARCH 31, 2023

The European Medicines Agency (EMA) has recommended HIPRA’s Covid-19 vaccine , Bimervax, as a Covid-19 booster. Available to people ages 16 years and above who have been vaccinated with a Covid-19 mRNA vaccine, EMA’s Human Medicines Committee concluded the vaccine is ready for marketing authorization in the EU, on 30 March.

Vaccination 277

Vaccination Vaccine Immune Response Antibody 277

XTalks

MARCH 31, 2023

BMS researchers on the mission will study the crystallization of an assortment of their biologics medicines in microgravity. By growing high quality crystal structures of protein-based therapeutics under microgravity, researchers can gain better insights into their complex structures and stability.

Protein 97

Protein Research Development Manufacturing 97

Pharmaceutical Technology

APRIL 26, 2023

MiNA Therapeutics has entered into a research collaboration and option licensing agreement with BioMarin Pharmaceutical to speed up the development of therapeutic ribonucleic acid activation (RNAa) candidates to treat rare genetic diseases. BioMarin may then license the assets fully to develop and commercialise them across the globe.

Development 130

Development Genetic Disease Genetics Gene Therapy 130

Pharmaceutical Technology

MAY 25, 2023

ElevateBio has raised $401m in a Series D financing round for advancing its technology platforms to expedite the design, production and development of cell and gene therapies. The technology platforms include the Life Edit gene editing platform, an RNA, cell, protein, vector engineering and induced pluripotent stem cells (iPSCs) platform.

Gene Therapy 243

Gene Therapy Gene Gene Editing Development 243

XTalks

JANUARY 21, 2025

The FDA has approved Datroway (datopotamab deruxtecan-dlnk), a TROP2-directed antibody-drug conjugate (ADC) for adults with unresectable or metastatic HR-positive, HER2-negative breast cancer, developed through a global collaboration between Daiichi Sankyo and AstraZeneca. Datroway leverages DXd technology to precisely target cancer cells.

Antibody 105

Antibody FDA Approval HR Trials 105

Pharmaceutical Technology

MARCH 10, 2023

On 10 March, the National Health Service Blood and Transplant (NHSBT) opened a new Clinical Biotechnology Centre (CBC) with the aim of improving the UK’s ability to develop and manufacture cell and gene therapies. Personalised medicines will also be developed at the centre.

Gene Therapy 264

Gene Therapy Manufacturing Gene Clinical Trials 264

Pharmaceutical Technology

JANUARY 4, 2023

The Gremlin1 protein was found to promote lineage plasticity while driving castration resistance in prostate cancer. Findings from a study, which was conducted by Transcenta and Shanghai Jiao Tong University scientists on TST003 to treat androgen receptor-negative/low prostate cancer, were published by Nature Cancer in May last year.

Antibody 242

Antibody In-Vivo In-Vitro Protein 242

Pharmaceutical Technology

APRIL 20, 2023

Targovax has unveiled plans to rebrand as Circio , reflecting its strategic shift to focus on expediting the development of its innovative circular RNA (circRNA) platform. In addition to new regulatory functionalities, this feature may result in stronger and more durable protein expression.

Gene Therapy 240

Gene Therapy RNA Gene Development 240

Scienmag

JULY 6, 2022

LA JOLLA—(July 6, 2022) Understanding how HIV replicates within cells is key for developing new therapies that could help nearly 40 million people living with HIV globally.

Protein 88

Protein Scientist Development Medicine 88